The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
A phase 1 study of the c-Met inhibitor tivantinib (ARQ 197, IND#112603) in children with relapsed or refractory solid tumors: A Children’s Oncology Group study.
James I. Geller
No relevant relationships to disclose
John Peter Perentesis
No relevant relationships to disclose
Charlotte H. Ahern
No relevant relationships to disclose
Rachel A. Kudgus
No relevant relationships to disclose
Elizabeth Fox
No relevant relationships to disclose
Susan Blaney
No relevant relationships to disclose
Brenda Weigel
No relevant relationships to disclose